At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- VHB937 (biological), VHB937 (biological), Placebo (other)
- How long the study runs
- Study runs about 64 months (dates as stated)
- About the drug or intervention
- VHB937 — biological: VHB937 solution for infusion · VHB937 — biological: VHB937 solution for infusion · Placebo — other: Solution for infusion
- Patient visit burden
- Not specified by the sponsor
In plain English
This study will look at the effects of a medicine called VHB937 in people with early Alzheimer's disease. This includes people with mild thinking and memory problems due to Alzheimer's disease, or mild Alzheimer's disease itself. The study is run by Novartis Pharmaceuticals.
Who can take part
- Men or women aged 50 to 85
- A diagnosis of mild thinking and memory problems (mild cognitive impairment) due to Alzheimer's disease, or mild Alzheimer's disease
- A Clinical Dementia Rating (CDR) global score of 0.5 or 1.0 (a scale used to measure memory and thinking)
- Alzheimer's disease confirmed by a spinal fluid test or an amyloid PET scan (a brain scan)
- A reliable study partner who can come with you to study visits
- If you already take Alzheimer's medicines (like donepezil-type drugs or memantine), you must be on a steady dose before starting the study treatment
Who may not be able to
- Dementia caused by something other than Alzheimer's disease, such as frontotemporal dementia, Parkinson's disease, dementia with Lewy bodies, Huntington's disease, or vascular dementia
- Heart problems or abnormal heart traces (ECG) that could make the study unsafe for you
- A mini-stroke (TIA) or stroke in the past 12 months
- Signs of liver or kidney disease or damage
- A current major depression that is not well controlled, or a history of schizophrenia or other long-term psychosis
- Other serious brain or nervous system conditions, such as serious brain infection, head injury, several concussions, epilepsy or repeated seizures
- Thoughts of suicide in the past 6 months, or suicidal behaviour in the past 2 years
- Cancer, HIV, hepatitis B, hepatitis C, uncontrolled thyroid disease, or uncontrolled diabetes
- Taking certain medicines that are not allowed in the study
What taking part involves
- • Taking the study medicine VHB937 — not stated — ask the trial team
- • Study tests and checks — not stated — ask the trial team
Time commitment: Not stated — ask the trial team (you would need a study partner to attend visits with you, and tests such as a spinal fluid test or brain scan may be needed to confirm diagnosis).
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 50 Years to 85 Years
- Who
- All
- Number of participants
- 407
- Started
- 2025-08-07
- Last checked
- 2026-06
Plain English Summary
What is this study?
- • Testing a new treatment for alzheimer's disease
- • Phase2 - 407 participants
- • This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension
Who can take part?
- • Ages 50 Years to 85 Years
- • Diagnosed with alzheimer's disease
Where?
- • Edinburgh - Novartis Investigative Site
- • Oxford - Novartis Investigative Site
- • Aberdeen - Novartis Investigative Site
- • London - Novartis Investigative Site
- • +5 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This is a multicentre, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early AD followed by an Extension. The double-blind part is 72 weeks long, followed by an extension.
More detail
The purpose of this study is to find out whether treatment with VHB937 is safe and beneficial in people with early Alzheimer's disease. The study will evaluate the safety of VHB937, as well as its effects on memory and other thinking abilities, on daily activities, and on changes in the brain. The study will also observe and measure how VHB937 is processed by the body and how the body responds to it.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 50 Years - 85 Years
- Who can join: All genders
What the study is looking for
- ✓Key Inclusion Criteria
- ✓Male or female participants 50 to 85 years of age
- ✓Diagnosis of Mild Cognitive Impairment (MCI) due to AD or mild AD
- ✓Clinical Dementia Rating (CDR) Global score of 0.5 or 1.0
- ✓Confirmation of AD based on cerebral spinal fluid (CSF) biomarkers or amyloid PET imaging
See the full criteria
Where Is This Study? (9 UK sites)
Novartis Investigative Site
Edinburgh EH12 5PJ, United Kingdom
Novartis Investigative Site
Oxford OX3 7JX, United Kingdom
Novartis Investigative Site
Aberdeen AB25 2ZH, United Kingdom
Novartis Investigative Site
London SE5 8AF, United Kingdom
Novartis Investigative Site
London W1G 9JF, United Kingdom
Novartis Investigative Site
London WC1N 3BG, United Kingdom
Novartis Investigative Site
Newcastle upon Tyne NE4 6BE, United Kingdom
Novartis Investigative Site
Salford M6 8HD, United Kingdom
Novartis Investigative Site
Southampton SO16 6YD, United Kingdom
How to Get in Touch
Novartis Pharmaceuticals
Sponsor contactCONTACT
Novartis Pharmaceuticals
Sponsor contactCONTACT